Grand Rounds

A Focus on Newly Diagnosed Multiple Myeloma

---

  

ABSTRACT

Multiple myeloma (MM) is an incurable plasma cell disorder that affects nearly 35,000 people annually. Over 149,000 individuals are estimated to live in the United States with MM. Research has generated a greater understanding of the pathology of this disease, now combined with mature clinical trial data that support the use of combination therapy in treatment. This article focuses on updated diagnosis, prognosis, and treatment of newly diagnosed patients. While the diagnosis of MM remains based on the 2014 International Myeloma Working Group (IMWG) guidelines, we review these and updated recommendations for the diagnosis and treatment of myeloma as well as relevant supportive care. The prognosis of patients with newly diagnosed MM relies heavily on the cytogenetic profile of the disease, along with other patient-specific risk factors. There are multiple first-line treatment options that combine three or four novel agents with the goal of reducing plasma cell burden and achieving minimal residual disease (MRD) negative status early in the treatment trajectory. Supportive care interventions aimed at minimizing the risk of infection and thromboembolic events, and protecting bone health are critical for maintaining quality of life and are as important as therapeutic treatment interventions.

Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
Introduction
A Focus on Newly Diagnosed Multiple Myeloma
A Focus on Relapsed Multiple Myeloma
A Focus on Special Populations in Relapsed Multiple Myeloma
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis

---

For access to the full length article, please sign in.